Comments to FDA: Developing Proprietary Names for Drugs

Share page:

Letter | Sep 15, 2014

Docket Number:
FDA-2014-D-0622

CHPA appreciates the opportunity to provide comments on the FDA’s draft guidance for industry entitled “Best Practices in Developing Proprietary Names for Drugs”. CHPA members hope the Agency will find the suggested revisions in these comments informative as the final version of the guidance is developed.

Related Posts